Last Updated: May 10, 2026

List of Excipients in API buprenorphine


✉ Email this page to a colleague

« Back to Dashboard


Excipients in NDA-approved (novel) drugs containing buprenorphine

Glossary
Company Tradename Ingredient NDC Excipient Potential Generic Entry
Indivior Inc SUBLOCADE buprenorphine 12496-0100 METHYLPYRROLIDONE
Indivior Inc SUBLOCADE buprenorphine 12496-0100 POLY(DL-LACTIC-CO-GLYCOLIC ACID)
Rhodes Pharmaceuticals LP BUPRENORPHINE buprenorphine 42858-750 ETHYL LEVULINATE
Rhodes Pharmaceuticals LP BUPRENORPHINE buprenorphine 42858-750 OLEYL OLEATE
Rhodes Pharmaceuticals LP BUPRENORPHINE buprenorphine 42858-750 POVIDONE
>Company >Tradename >Ingredient >NDC >Excipient >Potential Generic Entry

Subscribe to access the full database, or Start Trial

Excipients in ANDA-approved (generic) drugs containing buprenorphine

Company Ingredient NDC Excipient
Hikma Pharmaceuticals USA Inc buprenorphine 0054-0176 ANHYDROUS CITRIC ACID
Hikma Pharmaceuticals USA Inc buprenorphine 0054-0176 CROSPOVIDONE
Hikma Pharmaceuticals USA Inc buprenorphine 0054-0176 LACTOSE MONOHYDRATE
Hikma Pharmaceuticals USA Inc buprenorphine 0054-0176 MAGNESIUM STEARATE
Hikma Pharmaceuticals USA Inc buprenorphine 0054-0176 MANNITOL
>Company >Ingredient >NDC >Excipient

Subscribe to access the full database, or Start Trial

Detailed excipient profiles for buprenorphine

Excipient focus: .ALPHA.-TOCOPHEROL

Excipient focus: .ALPHA.-TOCOPHEROL ACETATE

Excipient focus: ACESULFAME POTASSIUM

Excipient focus: ALCOHOL

Excipient focus: ALUMINUM OXIDE

buprenorphine drug variants containing ALUMINUM OXIDE

Company Ingredient NDC
SpecGx LLC buprenorphine hydrochloride and naloxone hydrochloride dihydrate 0406-8005
Correct Rx Pharmacy Services Inc buprenorphine hydrochloride and naloxone hydrochloride dihydrate 24555-8005
Quality Care Products LLC buprenorphine hydrochloride and naloxone hydrochloride dihydrate 55700-901
Clinical Solutions Wholesale LLC buprenorphine hydrochloride and naloxone hydrochloride dihydrate 58118-8005
Bryant Ranch Prepack buprenorphine hydrochloride and naloxone hydrochloride dihydrate 71335-1725
>Company >Ingredient >NDC

Subscribe to access the full database, or Start Trial

Excipient focus: AMMONIA

Excipient focus: ANHYDROUS CITRIC ACID

Excipient focus: ANHYDROUS DEXTROSE

Excipient focus: ANHYDROUS LACTOSE

buprenorphine drug variants containing ANHYDROUS LACTOSE

Company Ingredient NDC
SpecGx LLC buprenorphine hydrochloride and naloxone hydrochloride dihydrate 0406-8005
Correct Rx Pharmacy Services Inc buprenorphine hydrochloride and naloxone hydrochloride dihydrate 24555-8005
Quality Care Products LLC buprenorphine hydrochloride and naloxone hydrochloride dihydrate 55700-901
Clinical Solutions Wholesale LLC buprenorphine hydrochloride and naloxone hydrochloride dihydrate 58118-8005
Bryant Ranch Prepack buprenorphine hydrochloride and naloxone hydrochloride dihydrate 71335-1725
>Company >Ingredient >NDC

Subscribe to access the full database, or Start Trial

Excipient focus: BUTYL ALCOHOL

Excipient focus: BUTYLATED HYDROXYANISOLE

Excipient focus: BUTYLATED HYDROXYTOLUENE

Excipient focus: CARBOXYMETHYLCELLULOSE SODIUM

Excipient focus: CELLULOSE, MICROCRYSTALLINE

Excipient focus: CITRIC ACID ACETATE

Excipient focus: CITRIC ACID MONOHYDRATE

Excipient focus: CORN SYRUP

Excipient focus: CROSCARMELLOSE SODIUM

Excipient focus: CROSPOVIDONE

Excipient focus: DEXTROSE

Excipient focus: DIBASIC POTASSIUM PHOSPHATE

Excipient focus: ETHYL LEVULINATE

Excipient focus: FD&C BLUE NO. 1

Excipient focus: FD&C RED NO. 40

Excipient focus: FD&C YELLOW NO. 6

Excipient focus: FERRIC OXIDE YELLOW

Excipient focus: FERROSOFERRIC OXIDE

Excipient focus: GLYCERYL DIOLEATE

Excipient focus: HYDROCHLORIC ACID

Excipient focus: HYDROXYETHYL CELLULOSE

Excipient focus: HYDROXYPROPYL CELLULOSE

Excipient focus: HYPROMELLOSE 2910

Excipient focus: HYPROMELLOSES

Excipient focus: ISOPROPYL ALCOHOL

Excipient focus: LACTOSE

Excipient focus: LACTOSE MONOHYDRATE

Excipient focus: LECITHIN, SOYBEAN

Excipient focus: LEVULINIC ACID

Excipient focus: MAGNESIUM STEARATE

Excipient focus: MALTITOL

Excipient focus: MALTODEXTRIN

Excipient focus: MANNITOL

Excipient focus: MENTHOL

Excipient focus: METHYLPARABEN

Excipient focus: METHYLPYRROLIDONE

Excipient focus: OLEYL OLEATE

Excipient focus: PEPPERMINT OIL

Excipient focus: POLY(DL-LACTIC-CO-GLYCOLIC ACID)

Excipient focus: POLYCARBOPHIL

Excipient focus: POLYETHYLENE GLYCOL

Excipient focus: POLYETHYLENE GLYCOL 8000

Excipient focus: POLYETHYLENE GLYCOLS

Excipient focus: POLYETHYLENE OXIDE 100000

Excipient focus: POLYETHYLENE OXIDE 1000000

Excipient focus: POLYETHYLENE OXIDE 200000

Excipient focus: POLYETHYLENE OXIDE 2000000

Excipient focus: POLYETHYLENE OXIDE 900000

Excipient focus: POTASSIUM HYDROXIDE

Excipient focus: POVIDONE

Excipient focus: POVIDONE K29/32

Excipient focus: POVIDONE K30

Excipient focus: POVIDONE K90

Excipient focus: PROPYLENE GLYCOL

Excipient focus: PROPYLPARABEN

Excipient focus: SACCHARIN SODIUM

Excipient focus: SHELLAC

Excipient focus: SILICON DIOXIDE

Excipient focus: SODIUM BENZOATE

Excipient focus: SODIUM CITRATE

Excipient focus: SODIUM HYDROXIDE

Excipient focus: SODIUM METABISULFITE

Excipient focus: SODIUM PHOSPHATE, DIBASIC, ANHYDROUS

Excipient focus: SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

Excipient focus: SODIUM STEARYL FUMARATE

buprenorphine drug variants containing SODIUM STEARYL FUMARATE

Company Ingredient NDC
SpecGx LLC buprenorphine hcl 0406-7012
PAI Holdings LLC dba Pharmaceutical Associates Inc and dba PAI Pharma buprenorphine hydrochloride 0121-1019
A-S Medication Solutions buprenorphine hydrochloride 50090-1571
A-S Medication Solutions buprenorphine hydrochloride 50090-7559
Akorn Operating Company LLC (dba Akorn) buprenorphine hydrochloride 50383-924
>Company >Ingredient >NDC

Subscribe to access the full database, or Start Trial

Excipient focus: STARCH, CORN

Excipient focus: SUCRALOSE

buprenorphine drug variants containing SUCRALOSE

Company Ingredient NDC
Actavis Pharma Inc buprenorphine and naloxone 0228-3154
Orexo US Inc buprenorphine hydrochloride and naloxone hydrochloride 54123-907
Orexo US Inc buprenorphine hydrochloride and naloxone hydrochloride 54123-914
Hikma Pharmaceuticals USA Inc buprenorphine hydrochloride and naloxone hydrochloride dihydrate 0054-0188
Major Pharmaceuticals buprenorphine hydrochloride and naloxone hydrochloride dihydrate 0904-7009
>Company >Ingredient >NDC

Subscribe to access the full database, or Start Trial

Excipient focus: TITANIUM DIOXIDE

Excipient focus: TRISODIUM CITRATE DIHYDRATE

Excipient focus: WATER

Excipient focus: ZEA MAYS

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links